BioFire Diagnostics, Inc. (fka Idaho Technology, Inc.), a Salt Lake City, Utah-based clinical diagnostics company, has raised $25m in new funding from Athyrium Opportunities Fund.
The company intends to use the capital to commercialize its FilmArray diagnostic platform and further develop additional panels.
Led by CEO Kirk Ririe, BioFire has developed the FDA-cleared, CE IVD marked, FilmArray Respiratory Panel (RP), which simultaneously tests 17 viral targets and three bacterial targets in approximately one hour. To date, BioFire has over 200 FilmArray RP units available in over 65 hospitals across the U.S and the EU.
Additional panels include, among others, a blood culture ID panel (currently in clinical trials), a gastrointestinal panel, and a meningitis panel.